Cardiff Oncology (CRDF) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Cardiff Oncology (CRDF) is Moderate Underperform.

The composite score behind that read is -0.30, weighing +0.31 of bullish evidence against -0.33 bearish.

Cardiff Oncology last closed at $1.09, +1.87% on the session.

Against the IVW growth benchmark the position is +2.03% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

18 graded predictions for CRDF so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Cardiff Oncology in the 10th percentile on return on equity, where 100 is best.

Cardiff Oncology is classified under Health Care / Biotechnology, with a market capitalisation of $83.24M.

StockMap tracks Cardiff Oncology as the 288th largest of the 377 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 198 Moderate Underperform, 166 Neutral and 13 Strong Underperform.

On that composite Cardiff Oncology ranks 266th of 377 in the group, against a group median of -0.21.